Argus
•
Sep 02, 2026
ACAD: Lowering target price to $30.00
Summary
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Alnylam Pharmaceuticals, Inc.
Sep 02, 2026
•
ALNY
ARWR: Lowering target price to $87.00
Sep 02, 2026
•
ARWR
EXEL: Raising target price to $63.00
Sep 02, 2026
•
EXEL
SRPT: Raising target price to $17.00
Sep 02, 2026
•
SRPT
HALO: Lowering target price to $118.00
Sep 02, 2026
•
HALO
